Abstract: Despite modest improvements in survival over the last several decades, the treatment of AML continues to present a formidable challenge. Most patients are elderly, and these individuals, as well as those with secondary, therapy-related, or relapsed/refractory AML, are particularly difficult to treat, owing to both aggressive disease biology and the high toxicity of current chemotherapeutic regimens. It has become increasingly apparent in recent years that coordinated interruption of cooperative survival signaling pathways in malignant cells is necessary for optimal therapeutic results. The modest efficacy of monotherapy with both cytotoxic and targeted agents in AML testifies to this. As the complex biology of AML continues to be elucidated, many “synthetic lethal” strategies involving rational combinations of targeted agents have been developed. Unfortunately, relatively few of these have been tested clinically, although there is growing interest in this area. In this article, the preclinical and, where available, clinical data on some of the most promising rational combinations of targeted agents in AML are summarized. While new molecules should continue to be combined with conventional genotoxic drugs of proven efficacy, there is perhaps a need to
rethink traditional philosophies of clinical trial development and regulatory approval with a focus on mechanism-based, synergistic strategies.

**Keywords:** AML; targeted therapies; rational combinations; HDAC inhibitors; CDK inhibitors; proteasome inhibitors; checkpoint abrogators; apoptosis; BH3-mimetics; Mcl-1

1. **Introduction**

Despite significant progress in recent years in unraveling the genetic basis of AML [1], resulting in improvements in our ability to prognosticate and predict outcomes with certain therapies [2], it remains a devastating disease. Cure rates for young adults remain 40%–45% at best, and those for patients older than 60 only around 10%–20% [3]. The anthracycline-cytarabine backbone, first introduced over 40 years ago [4], remains the cornerstone of initial therapy for most patients, and the only truly targeted agent to receive regulatory approval, gemtuzumab ozogamicin, has been voluntarily withdrawn from the market by the manufacturer [5,6]. Allogeneic hematopoietic stem cell transplantation (HSCT), with all its attendant risks, remains the best post-remission therapy for AML till date [7]. In a recent randomized, phase III trial [8], elacytarabine, a novel elaidic acid ester of cytarabine, failed to improve outcomes over physicians’ choice of one of seven different commonly used salvage regimens for patients with relapsed or refractory disease, who have a dismal prognosis (5-year overall survival from first relapse approximately 10%) [9]. Although initially greeted with considerable enthusiasm, no fms-like tyrosine kinase 3 (FLT3) inhibitor has been licensed for use [10], and resistance-conferring mutations in the FLT3 kinase have been described [11]. Recent approaches have involved exploring new therapeutic targets, e.g., isocitrate dehydrogenase (IDH) [12] or immune checkpoints, delivering conventional cytotoxic agents in fixed molar ratios [13,14], harnessing the power of T-cells against AML stem cell antigens (e.g., CD123) using dual affinity retargeting molecules (DARTs, Blood 2013; 122:360), etc.

Malignant cells are particularly vulnerable to the simultaneous disruption of multiple, cooperative survival signaling pathways [15,16]. In recent years, the concept of rationally combining targeted agents to defeat the redundancy of survival pathways in neoplastic cells has rapidly been gaining ground in a variety of tumor types [17]. Indeed, signaling pathways within cancer cells have been compared to other complex networks such as the internet or airplane flight patterns, characterized by both remarkable robustness and surprising vulnerability, such that very limited yet coordinated, specific targeting of the most critical “nodes” in the network can have dramatically outsized effects [18]. In this article, we review various “synthetic lethal” strategies using rational combinations of targeted drugs in AML.

2. **Combinations Involving Epigenetic Therapies**

2.1. **DNMTIs + HDACIs**

A particularly popular combination has been that of DNA methyltransferase inhibitors (DNMTIs) with histone deacetylase inhibitors (HDACIs). That epigenetic processes play a fundamental role in cancer causation and progression has been recognized for over a decade now [19]. Chromatin organization modulates gene transcription inasmuch as a more open, relaxed configuration of chromatin
(e.g., induced by HDACIs through histone acetylation) or demethylation of CpG islands in the promoter regions of genes (e.g., induced by DNMTIs, also known as hypomethylating agents, HMA) activates transcription of epigenetically silenced tumor suppressor genes, e.g., DNA repair genes [20]. The combination of DNMTIs and HDACIs synergistically triggers apoptosis and up-regulates microRNAs that, in turn, down-regulate oncogenes [21]. While the DNMTIs azacytidine and decitabine have clear single-agent activity in AML [22–25] and are widely used, response rates to HDACI monotherapy in AML and MDS have been more modest, of the order of 10%–20% [26] and none is approved for this indication, although the pan-HDACI pracinostat was recently granted “orphan drug” status by the FDA for AML [27]. As noted above, many trials of “dual epigenetic therapy” combining DNMTIs with HDACIs in AML have been conducted. In the recently published U.S. Leukemia Intergroup trial E1905 involving 97 patients with MDS and 52 with AML, addition of the class I-selective HDACI entinostat to azacytidine did not increase clinical response rates and was associated with pharmacodynamic antagonism [28]. Azacytidine was administered on days 1–10 of a 28-day cycle and entinostat on days 3 and 10 [28]. A randomized phase II study (NCT01305499) is currently underway to see if sequential, as opposed to concurrent, administration of entinostat will improve efficacy of this combination. In contrast, the combination of pracinostat with azacytidine yielded an 89% overall response rate (ORR) in a 9-patient pilot study in patients with higher risk categories of MDS and was very well tolerated [29].

2.2. Other DNMTI-Based Combinations

DNMTIs have also been combined with many other classes of targeted agents in AML. Based on the ability of the proteasome inhibitor bortezomib to up-regulate miR-29b, resulting in loss of transcriptional activation of several genes relevant to myeloid leukemogenesis, including DNA methyltransferases and receptor tyrosine kinases, a phase I trial of bortezomib and decitabine was conducted [30]. Seven of 19 patients overall achieved complete remission (CR) or complete remission with incomplete count recovery (CRi), although 5 of these were treatment-naïve [30]. The regimen was shown to down-regulate FLT3 [30]. These findings led to a phase II trial (NCT01420926) in the cooperative group setting in older patients with AML, but this trial was closed prematurely as it was deemed unlikely to meet its primary endpoint. In a phase II trial of sorafenib and azacytidine in 43 patients (37 evaluable) with FLT3-mutated AML and 0–7 (median 2) prior therapies, the ORR was 46%, including 27% CR/CRi [31]. FLT3 ligand levels did not rise to levels seen in prior studies of patients receiving cytotoxic chemotherapy [32]. Decitabine and midostaurin have been combined in a phase I study in patients with relapsed/refractory AML with or without FLT3 mutations based on in vitro evidence of synergy against FLT3-internal tandem duplication (FLT3-ITD+ cells [33]. Sequential administration was safe but concurrent administration was too toxic [33]. 57% of patients achieved stable disease (SD) or better; 25% had a complete hematologic response (CHR) [33]. Phase I trials combining decitabine with rapamycin [34] and with bexarotene [35] in patients with AML have been completed, with demonstration of safety but only modest outcomes. Both sequential [36] and concomitant [37] administration of azacytidine and lenalidomide have been studied in newly diagnosed elderly patients with AML in the phase I setting. Both combinations were well-tolerated, with ORRs of around 55% and CR/CRi rates ranging from 31% to 44% [36,37].
Given their efficacy and safety, and consequent widespread use as single agents for the treatment of patients with AML who are elderly and/or unfit for conventional chemotherapy, azacytidine and decitabine are increasingly being combined in clinical trials with a plethora of emerging, investigational targeted agents. Examples include volasertib (NCT02003573), a polo-like kinase 1 (PLK-1) inhibitor recently designated an “orphan drug” for AML [27], the first-in-class neddylation inhibitor MLN4924 (NCT01814826), the hedgehog inhibitor sonidegib (NCT02129101) and the Bcl-2-selective antagonist, ABT-199 (NCT02203773). In vitro, however, short interfering RNA (siRNA) silencing of the anti-apoptotic proteins Mcl-1 and Bcl-xL, but not Bcl-2, exhibited variable synergy with azacytidine [38].

2.3. BET Inhibitor-Based Combinations

A relatively recent development in the field of epigenetic targeting of chromatin networks in cancer has been the discovery of potent and specific small-molecule BET (bromodomain and extraterminal) inhibitors [39]. The bromodomain is a highly conserved motif of 110 amino acids found in proteins that interact with chromatin, such as transcription factors, histone acetylases and nucleosome remodelling complexes [40]. Bromodomain proteins function as chromatin “readers”, some of which have key roles in the acetylation-dependent assembly of transcriptional regulator complexes [41]. Bromodomain proteins recruit chromatin-regulating enzymes, including “writers” and “erasers” of histone modification, to target promoters and to regulate gene expression [40]. Lysine acetylation, a key mechanism that regulates chromatin structure, creates docking sites for bromodomains, and BET proteins regulate the expression of key oncogenes and anti-apoptotic proteins [41]. It was recently demonstrated that the BET protein (BRD4) antagonist JQ1 synergistically induced apoptosis of AML cells in combination with the HDACI panobinostat and improved the survival of mouse xenografts [42]. Additionally, JQ1 also synergized with the FLT3 tyrosine kinase inhibitors (TKIs) ponatinib or quizartinib to induce apoptosis of FLT3-ITD+ AML cells and overcame FLT3 TKI resistance-conferring mutations such as F691L and D835V [43]. Furthermore, the JQ1/panobinostat combination synergistically induced apoptosis of FLT3 TKI-resistant cells [43].

3. HDACI-Based Combinations Involving Non-Epigenetic Therapies (Table 1)

Distinct from their role as epigenetic modifiers, HDACIs exert a plethora of other actions (Figure 1) in neoplastic cells with a high degree of selectivity for the latter. These include down-regulation of anti-apoptotic and up-regulation of pro-apoptotic proteins (e.g., Bim), activation of the death receptor (extrinsic) pathway of apoptosis, induction of oxidative injury, interference with checkpoint and chaperone protein function (the latter through acetylation of Hsp90, leading to down-regulation of its “client” proteins), inhibition of DNA repair, interference with the function of co-repressors/co-factors, promotion of endoplasmic reticulum (ER) stress and disruption of aggresome function, JNK (C-Jun-N-terminal kinase) activation, STAT5 (signal transducer and activator of transcription 5) inhibition, proteasome inhibition, induction of autophagy and anti-angiogenic effects [26,44,45].
3.1. HDACIs + Proteasome Inhibitors

As noted above, the single-agent activity of HDACIs in AML is modest [26], and it has been appreciated for some time that the ultimate role of these agents may lie in combinatorial approaches [44,46]. An extensively studied rational combination has been that of HDACIs with proteasome inhibitors (PIs). While most advanced in multiple myeloma (MM) in terms of clinical development [47], this combination has been investigated in nearly every hematologic malignancy and may hold promise in AML [48,49]. Synergism between PIs and HDACIs stems from multiple mechanisms [50], including the inhibition by PIs of the pro-survival NF-κB pathway [51], which is activated by HDACIs and limits their lethality [52,53], disruption by HDACIs of aggresome formation [54], a physiologic response to proteasome inhibition [54], Hsp90 inhibition by HDACIs [55], both leading to marked accumulation of mis-folded proteins and accentuation of the proteotoxic stress induced by PIs, and multiple overlapping actions between these two classes of agents [26,44,45,56,57]. Additionally, there is evidence that the proteasome plays an important role in HDACI-induced apoptosis [58], and that HDACs are critical targets of bortezomib, at least in MM [59].

In pre-clinical studies, co-administration of sub-micromolar concentrations of the pan-HDACI belinostat with low nanomolar concentrations of bortezomib sharply increased apoptosis in AML and cell lines and primary blasts [48]. Synergistic interactions were associated with interruption of both canonical and non-canonical NF-κB signaling pathways, down-regulation of NF-κB-dependent pro-survival proteins (e.g., XIAP, Bcl-xL) and up-regulation of Bim [48]. These findings led to a phase I clinical trial of the combination in patients with relapsed/refractory or poor-prognosis previously untreated acute leukemias or higher risk MDS (NCT01075425) [49]. The maximum tolerated doses (MTDs) were determined to be 1.3 mg/m² IV of bortezomib on days 1, 4, 8 and 11 and 1000 mg/m² IV of belinostat.
on days 1–5 and 8–12 of a 3-week cycle. Of 35 response-evaluable subjects, one patient with mixed
lineage leukemia (\textit{MLL})-rearranged biphenotypic acute leukemia refractory to “7 + 3” and FLAG-Ida
(fludarabine, cytarabine, granulocyte colony stimulating factor, idarubicin) achieved a CR and went on
to an allogeneic HSCT; 4 had a partial remission (PR), 14 achieved stable disease (SD), and 16 had disease
progression. Four subjects discontinued study treatment due to adverse events (AEs). Overall, the
regimen was very well-tolerated. One patient with Janus kinase 2 (\textit{JAK2})-mutated myelofibrosis
transformed to AML remains on treatment beyond 31 cycles (manuscript in preparation). Efforts are
currently underway to better characterize (at a genomic level) the leukemias of the two patients who did
exceptionally well on this study.

3.2. HDACIs + CDK Inhibitors

Cyclin-dependent kinase inhibitors (CDKIs) represent an interesting class of agents capable of inducing
cell cycle arrest and apoptosis in malignant cells, particularly hematologic tumor types, which may be
more susceptible to inhibition of cell cycling and apoptosis induction [60]. Some of these agents,
\textit{i.e.}, those that inhibit cyclin T/CDK9, additionally inhibit global cellular transcription [61], thus
down-regulating short-lived proteins critically dependent on transcription for their maintenance, e.g., the
anti-apoptotic proteins XIAP and Mcl-1. Although no CDKI is currently approved, the FDA recently
granted “orphan drug” designation to the pan-CDKI flavopiridol (alvocidib) for AML [27].

Multiple pre-clinical studies have demonstrated robust synergism in AML cells between pan-CDKIs
such as flavopiridol or roscovitine and HDACIs, e.g., vorinostat, dacicostat, sodium butyrate [62–66].
Besides down-regulation of XIAP and Mcl-1, a major mechanism underlying these interactions was the
blockade by CDKIs of HDACI-induced up-regulation of the endogenous CDKI, p21\textsuperscript{WAF1/CIP1}. These
observations led to a phase I trial of the combination of alvocidib and vorinostat in patients with
relapsed/refractory or poor prognosis newly diagnosed acute leukemia or higher risk MDS [67]. The
alvocidib MTD was 20 mg/m\textsuperscript{2} IV load over 30 min followed by 20 mg/m\textsuperscript{2} infused over 4 h (“hybrid”
schedule of administration [68]) on days 1 and 8, in combination with vorinostat, 200 mg orally, three
times a day, for 14 days on a 21-day cycle [67]. No objective responses were achieved in 26 evaluable
patients (of 28 treated), although 13 exhibited SD [67].

3.3. HDACIs + TKIs

As discussed above, HDACIs, especially those that inhibit HDAC6, acetylate and thereby interfere
with the function of chaperone proteins, in particular Hsp90, consequently down-regulating several
pro-growth and pro-survival Hsp90 “client” proteins of critical importance in myeloid leukemias, e.g.,
breakpoint cluster region-Abelson (Bcr-Abl), mutant FLT3, c-Raf and Akt [55]. In the context of FLT3,
this phenomenon has also been reported with the class I-selective HDACI, entinostat [69]. Additionally,
HDACIs disrupt mitotic spindle checkpoints in neoplastic cells [70] and induce “mitotic slippage” [71].
These findings have provided the rationale for multiple preclinical studies that have demonstrated the
synergism between HDACIs and TKIs targeting Bcr-Abl [72–76], FLT3 [77], JAK [78,79] and aurora
kinases [80–82], which play critical roles in mitosis [83,84]. Unfortunately, the dual Bcr-Abl/aurora
kinase inhibitors MK-0457 (VX-680) [80,81] and KW-2449 [82] are no longer in development. To our
knowledge, this concept has not been evaluated in clinical trials in AML. However, at least two ongoing
clinical trials are testing the combination of the HDACI panobinostat and the JAK1/2 inhibitor ruxolitinib in patients with myelofibrosis (NCT01693601, NCT01433445). In chronic myeloid leukemia (CML), the HDACI+TKI strategy has been reported to target stem cells [85]. Synergistic anti-leukemic interactions between AT9283, a multi-targeted TKI that inhibits Bcr-Abl, FLT3, JAK and aurora kinases [86–88], and entinostat have been observed in Bcr-Abl+ cells, including those bearing the gatekeeper mutation T315I, as well as in AML cells, both FLT3-mutated and -wild type (Nguyen and Grant, unpublished observations). Considering that mutations that confer resistance to one of the most promising FLT3 TKIs, quizartinib, have been described [11], this strategy may yet prove valuable in AML.

3.4. HDACIs + G2/M Checkpoint Abrogators

Cell cycle checkpoints, part of the DNA damage response (DDR) network, are in-built safety mechanisms the activation of which helps preserve genomic integrity by halting cell division upon the occurrence of DNA damage and allowing time for DNA repair [89]. If repair fails, checkpoints trigger apoptosis [90]. The major cell cycle checkpoints are the G1/S, intra-S-phase and G2/M checkpoints. Checkpoint dysfunction is common in human cancers and is considered a pathologic hallmark of neoplastic transformation [91]. In particular, the G1/S-checkpoint is frequently dysfunctional because of p53 and/or Rb mutations, making malignant cells overtly reliant on the intra-S-phase and G2/M checkpoints [92]. Although p53 mutations are uncommon in de novo AML [93], overexpression of Mdm2, the negative regulator of p53, is common [94,95], as is disruption of regulated p53 expression [96], and p53 mutations are common in secondary AML [97–100]. p53 mutations are strongly associated with a complex aberrant karyotype in AML [101]. In these patients, p53 alterations are associated with older age, genomic complexity, specific DNA copy number alterations, monosomal karyotypes, and a dismal outcome [102]. When present, p53 mutations confer an extremely poor prognosis [93,103,104] that is not overcome even by allogeneic HSCT [105]. Finally, recent studies indicate that leukemic cells expressing FLT3-ITD display defective DNA repair mechanisms [106,107]. In the presence of a dysfunctional G1/S checkpoint, G2/M checkpoint abrogation (e.g., with small-molecule inhibitors of the Chk1 or Wee1 kinases) prevents cancer cells from repairing DNA damage, forcing them into a premature and lethal mitosis (“mitotic catastrophe”) [92].

Given that HDACIs induce DNA damage [108] and inhibit DNA repair, both homologous [109] and non-homologous end-joining (NHEJ) [110], and the ability of these agents and Hsp90 inhibitors to down-regulate proteins that play major roles in the DDR network such as ATR (ATM and Rad3 related), Chk1 and Wee1 [111–114], the combination of HDACIs with G2/M checkpoint abrogators has considerable theoretical appeal [45]. Indeed, synergistic potentiation of vorinostat-mediated apoptosis by the Chk1 inhibitor MK-8776 has been demonstrated in various AML cell lines, both p53-wild type and -deficient, as well as in those bearing FLT3-ITD [115]. Furthermore, the regimen was active against primary AML blasts, particularly against the putative leukemia initiating cell (LIC, CD34-CD38-CD123+) population [115]. However, clinical trials of Chk1 inhibitors have concentrated on combining them with conventional genotoxic agents, and no trials have explored simultaneous HDAC and Chk1 inhibition.

The Wee1 kinase has recently emerged as a novel therapeutic target in AML [116–118]. Although efforts at the preclinical level to develop AZD-1775, a potent, small-molecule inhibitor of Wee1 [119,120],
in AML have focused largely on using it to circumvent resistance to cytarabine [121,122], a sound rationale exists for combining this agent with HDACIs in AML. Of note, AZD-1775 may be effective regardless of p53 functionality [120,122]. During interphase, Wee1 phosphorylates the cyclin B/CDK1 (also known as cdc2) complex at Tyr15 to inactivate it, and Wee1 inhibition causes forced activation of CDK1, premature mitotic entry and impairment of homologous recombination [123]. Activation of cyclin B/CDK1 (cdc2) requires dephosphorylation by the CDC25 phosphatases (A, B and C) [89]. Notably, inactivation of cdc2 (CDK1) involves phosphorylation at two inhibitory sites, i.e., Tyr15 and Thr14, and dephosphorylation of both sites is necessary for full cyclin B/CDK1 (cdc2) activation. Upon G2/M checkpoint activation, ATR/Chk1 phosphorylates (and thereby inhibits) CDC25A, -B and -C, thus preventing premature mitotic entry [89].

While Chk1 is a positive regulator of Wee1 (through stimulatory phosphorylation), Wee1 inhibition results in compensatory activation of Chk1, leading to phosphorylation of cyclin B/CDK1 (cdc2) at Thr14 [124], a therapeutically undesirable, putatively cytoprotective effect. Concomitant administration of an HDACI may circumvent this problem by down-regulating Chk1 [111]. While this could also be achieved by combined Chk1 and Wee1 inhibition [124–127], HDACIs carry the additional advantages of inducing DNA damage and inhibiting DNA repair. Preclinical studies in AML with the combination of vorinostat and AZD-1775 have shown striking synergism, irrespective of p53 and FLT3 mutational status, including in “LIC”s, primary AML blasts and in a xenograft mouse (flank) model [128]. Importantly, whereas AZD-1775 treatment of leukemia cells triggered cyclin B/CDK1 (cdc2) Tyr15 dephosphorylation, it also induced Chk1 activation and Thr14 phosphorylation [128]. However, HDACI co-administration abrogated these undesirable phenomena, resulting in pronounced Tyr15 and Thr14 dephosphorylation, and full cyclin B/CDK1 (cdc2) activation, accompanied by premature mitotic entry and DNA damage [128]. These data and similarly promising results obtained upon substituting the recently approved HDACI belinostat for vorinostat have sparked interest in a National Cancer Institute-sponsored phase I clinical trial of the AZD-1775/belinostat combination in patients with relapsed/refractory AML/MDS as well as treatment-naïve poor prognosis patients with AML.

### 3.5. Other HDACI-Based Rational Combinations in AML

Aside from the strategies discussed above, HDACIs may potentially be successfully combined with a number of other investigational agents in AML. The first-in-class polo-like kinase 1 (PLK1) inhibitor volasertib was recently granted first “breakthrough” [129], and then “orphan drug” designation [27] for AML. This agent is currently in clinical trials in combination with low dose cytarabine (NCT01721876), decitabine (NCT02003573) or intensive chemotherapy (NCT02198482). PLK1 is critical to mitotic progression [130,131], and plays an important role in the DDR network [132,133], interacting with multiple checkpoint proteins [134]. As Bcr-Abl signals downstream to PLK1 [135], the PLK1 inhibitor BI2536 was studied in combination with vorinostat in CML cell lines and primary cells [136]. Pronounced synergism was observed in both imatinib-sensitive and -resistant Bcr-Abl+ cells, both in vitro and in vivo [136]. Enhanced Bcr-Abl pathway inhibition did not appear to be the predominant mechanism for lethality of the PLK1 inhibitor/HDACI combination; rather, it seemed to be potentiation of DNA damage and disabling of the DDR [136]. Given that pracinostat has also received “orphan drug” designation for AML [27], the combination of volasertib and pracinostat warrants attention in this disease.
The first-in-class inhibitor of protein “neddylation”, MLN4924 [137], is another promising agent in AML [138,139] currently in clinical trials with azacytidine (NCT01814826). Targeting protein neddylation, a critical pathway of protein degradation located upstream of the proteasome [140], allows for more selective interference with protein turnover, potentially yielding a better therapeutic index for these drugs as compared to PIs [141,142]. At least in theory, combination of this agent with HDACIs is particularly appealing for several reasons [45]. MLN4924 inhibits NF-κB (activated by HDACIs [52,53]) and leads to ROS generation and DNA damage in AML cells [138]. Additionally, MLN4924 induces DNA re-replication, an irreversible cellular insult that leads to apoptosis, by interfering with the turnover of the cullin-RING ligase substrate CDT1, a critical DNA replication licensing factor, in S-phase [143,144]. Finally, MLN4924 appears to trigger a cytoprotective autophagic response [145,146], that could be counteracted by HDACIs [147,148].

The phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a cellular growth, proliferation, motility and survival signaling axis [149] that represents one of the most frequently dysregulated pathways in cancer [150], including AML [151,152], where activation of the pathway has been shown to be required for cell survival [153,154]. In AML, Akt activation (phosphorylation at Thr<sup>308</sup>/Ser<sup>473</sup>) variably occurs in 50–80% of patients [155,156]; hence, there is considerable interest in targeting the PI3K/Akt/mTOR axis in AML [157]. Although mTOR inhibitors have been commercially available for some time for the treatment of various solid tumors, the first PI3K (delta isoform) inhibitor to receive regulatory approval, idelalisib [158,159], has only very recently arrived on the market, fueling intense interest in this class of agents. Synergistic interactions between PI3K or Akt inhibitors and HDACIs have been documented in AML cells [160,161]. Combined HDAC and PI3K inhibition led to a marked increase in apoptosis associated with Bcl-2 and Bid cleavage, XIAP and Mcl-1 down-regulation, mitogen activated protein kinase (MAPK) inactivation and blockade of HDACI-mediated induction of p21<sup>CIP1/WAF1</sup> [160]. Inactivation of extracellular signal-regulated kinase (ERK) was also seen with HDACI/perifosine (Akt inhibitor) co-treatment of AML cells, along with Akt inhibition, JNK activation, ROS and ceramide generation, leading to striking increases in mitochondrial injury and apoptosis [161].

4. Priming Apoptosis

The Bcl-2 family of proteins stands at the crossroads of cellular survival and death, and the pro- and anti-apoptotic members of this family regulate the intrinsic, or mitochondrial, pathway of apoptosis [162]. The seminal event in this pathway of programmed cell death, “mitochondrial outer membrane permeabilization (MOMP)”, commits the cell to apoptosis and constitutes a “point of no return” triggered by the apoptosis “effectors” Bax and Bak [163]. Under normal conditions, the pro-survival anti-apoptotic proteins (mainly Bcl-2, Bcl-xL and Mcl-1) sequester the apoptosis effectors; thus, the latter need to be released from such binding in order to induce MOMP [163]. While some of the so-called “BH3-only” proteins (e.g., Bim, tBid and Puma) can directly activate Bax and Bak [163], most function as “sensitizers”, <i>i.e.</i>, they displace the apoptosis effectors from their association with the anti-apoptotic proteins [164], a function mimicked by the “BH3-mimetic” class of drugs. The Bcl-2 family is of profound importance in the pathogenesis, prognosis, chemoresistance and treatment of AML [165].
The discovery of ABT-737, a specific “BH3-mimetic” antagonist of Bcl-2 and Bcl-xL, demonstrated for the first time that specific protein-protein interactions could be targeted by small molecules, and ushered in a new era in cell death research [166]. Subsequently, an oral analog with improved pharmacological properties, ABT-263 (navitoclax), was developed [167]. This agent demonstrated promising efficacy in patients with relapsed/refractory CLL in a phase I trial [168], but the occurrence of dose-dependent thrombocytopenia owing to on-target Bcl-xL inhibition [169] in early clinical trials [168,170–172] precluded continued development of this agent. There is also some evidence that Bcl-xL-inhibitory BH3-mimetics can undermine platelet function [173]. These observations led to the development, by reverse engineering of navitoclax, of ABT-199 (GDC-0199), a highly selective Bcl-2 antagonist that retains significant anti-tumor activity while sparing platelets [174]. This agent appears highly effective in CLL [175], and at least at the preclinical level, holds substantial promise in AML [176]. Of note, oblimersen, an anti-sense oligonucleotide against Bcl-2, failed in phase III clinical trials when added to chemotherapy in older patients in AML [177], despite improving 5-year survival when combined with fludarabine and cyclophosphamide in patients with relapsed/refractory CLL [178]. This agent was not, however, ever approved for use.

Neither ABT-199 (GDC-0199) nor navitoclax inhibits Mcl-1, which is fundamental to the pathogenesis and maintenance of AML [179] and the main determinant of resistance to ABT-737 [180,181]. The pan-BH3-mimetic obatoclax, which inhibited Mcl-1 in addition to Bcl-2/-xL [182], has been discontinued due to the occurrence of severe, infusional neurologic toxicity, e.g., ataxia, euphoria and somnolence. For these reasons, a number of combination strategies (Figure 2) have been explored preclinically to simultaneously target multiple arms of the apoptotic regulatory machinery, i.e., Mcl-1 and Bcl-2/-xL [183,184]. Since Mcl-1 is a short-lived protein critically dependent on active transcription and translation for its maintenance, some of these strategies have used cyclin T/DCK9 inhibitors or sorafenib to repress cellular transcription [61] or translation [185], respectively. Thus, roscovitine dramatically increases ABT-737 lethality in AML cells by simultaneously and cooperatively inducing Bak activation and Bax translocation [186]. In the case of sorafenib, synergistic interactions with both ABT-737 [187] and obatoclax [188] have been reported, in the latter case with the induction of cytoprotective autophagy that could be inhibited pharmacologically, potentiating the lethality of the regimen [188]. In these studies, both Bim up-regulation and Mcl-1 down-regulation were noted, and synergism was demonstrated not only in AML cell lines, but also in patient-derived cells and in a xenograft mouse model [187,188]. HDACIs, which up-regulate Bim, have also been combined with both ABT-737 [189] and obatoclax [190]. HDACI-induced Bim is largely sequestered by Bcl-2 and Bcl-xL, which it is released by ABT-737, activating Bax and Bak and triggering MOMP [189]. Both mocetinostat and vorinostat display synergistic anti-leukemia activity with obatoclax, but in this setting, cell death is attributable to activation of both apoptosis and autophagy [190]. Finally, mitogen activated protein kinase kinase (MEK) inhibitors have been shown to synergize with ABT-737, both in vitro (including in “LICs”) and in vivo, through the same mechanism, i.e., down-regulation of Mcl-1, which is induced by ABT-737 via ERK activation [191].
Table 1. HDACI-based rational combinations with non-cytotoxic, non-epigenetic agents in AML.

| Partner Agent Class | Mechanism(s) of Synergy                                                                 | Clinical Trials, if any                                                                 | Reference(s) |
|---------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------|
| Proteasome inhibitors (PIs), e.g., bortezomib, carfilzomib, ixazomib, oprozomib, marizomib | NF-κB inhibition by PIs (activated by HDACIs); inhibition by HDACIs of aggresome formation and of Hsp90→increased proteotoxic stress, multiple other actions | NCT01075425; closed to accrual; phase I; enrolled primarily relapsed/refractory patients with AML; one CR, one prolonged SD (see text) | [48,49] |
| Cyclin-dependent kinase inhibitors (CDKIs), e.g., flavopiridol (alvocidib), roscovitine (seliciclib), dinaciclib, palbociclib | Down-regulation of XIAP and Mcl-1 by cyclin T/CDK9 inhibitors via transcriptional repression; blockade by CDKIs of HDACI-induced up-regulation of p21 | NCT00278330; completed; phase I; enrolled primarily relapsed/refractory patients with AML; no objective responses; 50% achieved SD | [62–67] |
| Multi-kinase inhibitors (that inhibit aurora kinases and critical signaling molecules in AML, e.g., FLT3, JAK2), e.g., MK-0457, KW-2449, AT9283 | Down-regulation of Hsp90 “client” proteins by HDACIs, e.g., FLT3, c-Raf, Akt, JAK2, disruption of mitotic spindle checkpoints and induction of mitotic “slippage” | NCT00278330; completed; phase I; enrolled primarily relapsed/refractory patients with AML; no objective responses; 50% achieved SD | [77,79,81] |
| Checkpoint abrogators, e.g., MK-8776 (Chk1 inhibitor), AZD-1775 (Wee1 inhibitor) | Induction of DNA damage and inhibition of DNA repair by HDACIs; down-regulation of ATR, Chk1 and Wee1 by HDACIs via Hsp90 inhibition | Phase I clinical trial of Wee1 inhibitor AZD-1775 and belinostat in patients with relapsed/refractory or poor-prognosis AML in development | [115,128] |
| Polo-like kinase inhibitors, e.g., BI2536, volasertib | Potentiation of DNA damage and disruption of the DNA damage response by HDACIs | NCT00278330; completed; phase I; enrolled primarily relapsed/refractory patients with AML; no objective responses; 50% achieved SD | [136] |
| Protein neddylation inhibitors (MLN4924) | Inhibition of NF-κB (activated by HDACIs) by MLN4924, ROS generation and induction of DNA damage by MLN4924 as well as by HDACIs, opposing effects on autophagy | Manuscript in preparation | |
| BH3-mimetics, e.g., obatoclax, navitoclax, venetoclax | Up-regulation of Bim by HDACIs, which is released from Bcl-2 and Bcl-xL by ABT-737, activation of cytotoxic autophagy (obatoclax) | NCT00278330; completed; phase I; enrolled primarily relapsed/refractory patients with AML; no objective responses; 50% achieved SD | [189,190] |
| PI3K/Akt/mTOR pathway inhibitors, e.g., LY294002, buparlisib, idelalisib, duvelisib (PI3K inhibitors), perifosine (Akt inhibitor), BEZ235 (PI3K/mTOR inhibitor) | Bcl-2 and Bid cleavage, down-regulation of Mcl-1 and XIAP, MAPK/ERK inactivation, JNK activation, ROS generation, blockade of HDACI-mediated induction of p21 | NCT00278330; completed; phase I; enrolled primarily relapsed/refractory patients with AML; no objective responses; 50% achieved SD | [160,161] |

Abbreviations: HDACI, histone deacetylase inhibitor; NF-κB, nuclear factor kappa B; Hsp90, heat shock protein 90; AML, acute myeloid leukemia; CR, complete remission; SD, stable disease; DNA, deoxyribonucleic acid; ROS, reactive oxygen species; Bcl-2, B-cell lymphoma 2; XIAP, X-linked inhibitor of apoptosis; Mcl-1, myeloid cell leukemia 1; Bcl-xL, B-cell lymphoma extra long; MAPK, mitogen activated protein kinase; ERK, extracellular signal-regulated kinase; FLT3, fms-like tyrosine kinase 3; JAK2, Janus associated kinase 2; JNK, C-Jun N-terminal kinase; PI3K, phosphatidylinositol-3-kinase; mTOR, mammalian target of rapamycin; ATR, ATM (ataxia telangiectasia mutated) and Rad3-related; Chk1, checkpoint kinase 1.
Figure 2. Should be: Mechanisms of potentiation of BH3-mimetic lethality by strategies targeting Mcl-1. Reproduced, with permission, from [184].

A particularly strong rationale exists [192] for combining BH3-mimetics, e.g., ABT-737, with dual inhibitors of PI3K and mTOR, e.g., NVP-BEZ235, PI-103 or GDC-0980 in AML (Figure 3). Akt regulates a wide range of target proteins that control cellular proliferation, survival, growth and other processes, including Bim, Bad and Bax, the forkhead box O (FOXO) transcription factors (which mediate apoptosis by activating the transcription of pro-apoptotic genes such as FasL and Bim), Mdm2, glycogen synthase kinase 3 (GSK3) isoforms (which down-regulate cyclin D1 and Myc), procaspase 9, IκB kinase (the negative regulator of NF-κB), the endogenous CDKI p27KIP1 and Chk1 [193,194]. Importantly, mTORC1, a major downstream effector of Akt, is often not only under the control of PI3K/Akt signaling [195], and conversely, mTOR inhibition can lead to feedback activation of PI3K/Akt and MEK/ERK, arguing for simultaneous inhibition of both PI3K/Akt and mTOR [196]. Some of these agents have shown clear preclinical evidence of activity in AML [197,198]. Finally, as noted above [160,161] and in sharp contrast to other tumor types [199], in AML cells, PI3K/Akt inhibitors may disrupt, rather than activate, the complementary Ras/Raf/MEK/ERK survival signaling pathway, activated in >80% of AML samples [200], through an unknown mechanism. For these reasons, while PI3K inhibitors (e.g., GDC-0941) [201] and mTOR inhibitors plus MEK inhibitors (e.g., AZD-8055 plus selumetinib) [202] demonstrate synergestic pro-apoptotic effects with ABT-737 in AML cell lines and patient-derived blasts, accompanied by Bim up-regulation, Mcl-1 down-regulation and Bax activation, dual PI3K/mTOR inhibitors may, in fact, be the superior partner for ABT-737 [192]. Indeed, these agents (e.g., NVP-BEZ235, PI-103) synergistically increased ABT-737-mediated cell death in multiple leukemia cell lines and primary AML specimens, as well as significantly diminished tumor growth and prolonged animal survival in a subcutaneous xenograft model [203]. PI3K/mTOR inhibitors markedly down-regulated Mcl-1, apparently through a GSK3-mediated mechanism, but increased Bim binding to
Bcl-2/Bcl-xL; the latter effect was abrogated by ABT-737 [203]. Responding, but not non-responding, primary samples exhibited basal AKT phosphorylation, suggesting that basal Akt activation/addiction may predict for success of this therapeutic strategy [203]. Studies are underway to see if these findings can be extended to the combination of GDC-0980 and ABT-199 (GDC-0199).

**Figure 3.** Hypothetical model of interactions between PI3K/AKT/mTOR pathway inhibitors and Bcl-2 antagonists. Reproduced, with permission, from [192].

5. Other Rational Combinations

The PI-CDKI combination of bortezomib and alvocidib is synergistic in myeloid leukemia cells [204,205] but, to our knowledge, this combination has been tested clinically only in patients with relapsed or refractory indolent B-cell neoplasms, including MM [206,207]. In AML cells, synergistic induction of cell death was accompanied by down-regulation of Mcl-1 and XIAP, JNK activation, NF-κB inhibition, cdc2 activation and diminished expression of p21WAF1/CIP1 [204]. In CML cells, similar findings were noted, in addition to Bcr-Abl down-regulation, STAT3/5 inhibition and diminished phosphorylation of Lyn, Hck, CrkL, and Akt [205]. The regimen effectively induced apoptosis in imatinib-resistant cells characterized by reduced expression of Bcr-Abl but a marked increase in expression/activation of Lyn and Hck [205].

Dramatic potentiation of CDKI-induced apoptosis by inhibitors of PI3K has been demonstrated in AML cell lines and primary patient-derived blasts, accompanied by diminished Bad phosphorylation, induction of Bcl-2 cleavage, and down-regulation of XIAP and Mcl-1 [208]. In contrast, synergistic enhancement of alvocidib-induced apoptosis was not observed with inhibitors of MEK/ERK or of...
mTOR [208]. Much more recently, PIK-75, a compound that transiently blocks CDK7/9, leading to transcriptional suppression of Mcl-1, and also targets the p110α isoform of PI3K has been shown to rapidly induce apoptosis of AML cells, significantly reduce leukemic burden and increase the survival of mouse xenografts without overt toxicity [209].

The observation that inhibition of Chk1 triggers marked ERK1/2 activation, which can be blocked by MEK inhibitors [210] or Ras-targeting agents such as statins [211] or farnesyltransferase inhibitors [212], leading to striking increases in apoptosis and dramatically enhanced lethality, both in vitro and in vivo, along with a requirement for ERK1/2 activation in progression across the G2/M boundary and through mitosis [213], as well as functional roles for MEK/ERK signaling in the DDR [214,215] provide the rationale for combined inhibition of Chk1 and the Ras/Raf/MEK/ERK pathway in AML [90]. Furthermore, these strategies act independently of p53 mutational status [90]. However, these early studies [210–212] used UCN-01 (7-hydroxystaurosporine), which functions as a CDKI and as an inhibitor of protein kinase C (PKC), in addition to inhibiting Chk1. The recent withdrawals of several investigational Chk1 inhibitors has hampered translation of this concept. However, given the modest efficacy of selumetinib monotherapy in AML [216], combined Chk1 and MEK inhibition, most recently explored in MM [217], could also warrant attention in AML.

6. Conclusions

The number of rational combinations of targeted agents that are possible in AML and may be effective, at least in theory, is virtually limitless. The biggest challenge, therefore, is how to most judiciously choose the most promising combinations and bring them forward into clinical trials, which are costly and time-consuming. For these reasons, consideration should also be given to identifying the biologic subtypes of AML most likely to benefit from a given combination, as illustrated by the suggestion that basal Akt activation might predict for efficacy of a strategy simultaneously targeting Bcl-2/-xL and PI3K/mTOR. Additionally, attention needs to be paid to better trial designs, e.g., adaptive designs, to get us answers to the biggest challenges confronting our patients in the most expeditious manner possible. Finally, the current paradigm for regulatory approval of new drugs in the United States discourages manufacturers from venturing into combinations of unapproved agents, and slows the pace of therapeutic progress. As a result, very few of the combinations discussed in this article have been tested in patients. While a complex problem, this is one that will require a concerted effort by lawmakers, researchers, industry and the concerned public to effect real change in the fight against cancer in general, and AML in particular.

Author Contributions

Prithviraj Bose wrote the manuscript. Steven Grant critically reviewed the manuscript for important intellectual content.

Conflicts of Interest

The authors declare no conflict of interest.
Acknowledgements

This work was supported in part by the following awards (SG): R01 CA167708 and P50 CA142509 from the National Institutes of Health, and an award from the Leukemia and Lymphoma Society (R1906-14).

References

1. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult *de novo* acute myeloid leukemia. *N. Engl. J. Med.* 2013, 368, 2059–2074.
2. Patel, J.P.; Gonen, M.; Figueroa, M.E.; Fernandez, H.; Sun, Z.; Racevskis, J.; van Vlierberghe, P.; Dolgalev, I.; Thomas, S.; Aminova, O.; et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N. Engl. J. Med.* 2012, 366, 1079–1089.
3. Burnett, A.K. Treatment of acute myeloid leukemia: Are we making progress? *Hematol. Am. Soc. Hematol. Educ. Program* 2012, 2012, 1–6.
4. Yates, J.W.; Wallace, H.J., Jr.; Ellison, R.R.; Holland, J.F. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. *Cancer Chemother. Rep.* 1973, 57, 485–488.
5. Ravandi, F.; Estey, E.H.; Appelbaum, F.R.; Lo-Coco, F.; Schiffer, C.A.; Larson, R.A.; Burnett, A.K.; Kantarjian, H.M. Gemtuzumab ozogamicin: Time to resurrect? *J. Clin. Oncol.* 2012, 30, 3921–3923.
6. Rowe, J.M.; Lowenberg, B. Gemtuzumab ozogamicin in acute myeloid leukemia: A remarkable saga about an active drug. *Blood* 2013, 121, 4838–4841.
7. Stelljes, M.; Krug, U.; Beelen, D.W.; Braess, J.; Sauerland, M.C.; Heinecke, A.; Liggens, S.; Sauer, T.; Tschanker, P.; Thoenissen, G.B.; et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: A prospective matched pairs analysis. *J. Clin. Oncol.* 2014, 32, 288–296.
8. Roboz, G.J.; Rosenblat, T.; Arellano, M.; Gobbi, M.; Altman, J.K.; Montesinos, P.; O’Connell, C.; Solomon, S.R.; Pigneux, A.; Vey, N.; et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. *J. Clin. Oncol.* 2014, 32, 1919–1926.
9. Forman, S.J.; Rowe, J.M. The myth of the second remission of acute leukemia in the adult. *Blood* 2013, 121, 1077–1082.
10. Levis, M. FLT3 mutations in acute myeloid leukemia: What is the best approach in 2013? *Hematol. Am. Soc. Hematol. Educ. Program* 2013, 2013, 220–226.
11. Smith, C.C.; Wang, Q.; Chin, C.S.; Salerno, S.; Damon, L.E.; Levis, M.J.; Perl, A.E.; Travers, K.J.; Wang, S.; Hunt, J.P.; et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. *Nature* 2012, 485, 260–263.
12. Chaturvedi, A.; Araujo Cruz, M.M.; Jyotsana, N.; Sharma, A.; Yun, H.; Gorlich, K.; Wichmann, M.; Schwarzer, A.; Preller, M.; Thol, F.; et al. Mutant IDH1 promotes leukemogenesis *in vivo* and can be specifically targeted in human AML. *Blood* 2013, 122, 2877–2887.
13. Lancet, J.E.; Cortes, J.E.; Hogge, D.E.; Tallman, M.S.; Kovacsovics, T.J.; Damon, L.E.; Komrokji, R.; Solomon, S.R.; Kolitz, J.E.; Cooper, M.; et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs. cytarabine/daunorubicin in older adults with untreated AML. *Blood* 2014, 123, 3239–3246.

14. Cortes, J.E.; Goldberg, S.L.; Feldman, E.J.; Rizzi, D.A.; Hogge, D.E.; Larson, M.; Pigneux, A.; Recher, C.; Schiller, G.; Warzocha, K.; et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. *Cancer* 2015, 121, 234–242.

15. Grant, S. Is the focus moving toward a combination of targeted drugs? *Best Pract. Res. Clin. Haematol* 2008, 21, 629–637.

16. Bose, P.; Grant, S. Complementary combinations: What treatments will become key to the battle against acute myelogenous leukemia? *Expert Rev. Hematol.* 2012, 5, 475–478.

17. Kaiser, J. Combining targeted drugs to stop resistant tumors. *Science* 2011, 331, 1542–1545.

18. Westin, J.R. Busting robustness: Using cancer’s greatest strength to our advantage. *Future Oncol.* 2015, 11, 73–77.

19. Baylin, S.B.; Jones, P.A. A decade of exploring the cancer epigenome—Biological and translational implications. *Nat. Rev. Cancer* 2011, 11,726–734.

20. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. *Nat. Rev. Genet.* 2002, 3, 415–428.

21. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. *Cell* 2007, 128, 683–692.

22. Fenaux, P.; Muffti, G.J.; Hellstrom-Lindberg, E.; Santini, V.; Gattermann, N.; Germing, U.; Sanz, G.; List, A.F.; Gore, S.; Seymour, J.F.; et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. *J. Clin. Oncol.* 2010, 28, 562–569.

23. Cashen, A.F.; Schiller, G.J.; O’Donnell, M.R.; DiPersio, J.F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. *J. Clin. Oncol.* 2010, 28, 556–561.

24. Blum, W.; Garzon, R.; Klisovic, R.B.; Schwind, S.; Walker, A.; Geyer, S.; Liu, S.; Havelange, V.; Becker, H.; Schaaf, L.; et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. *Proc. Natl. Acad. Sci. USA* 2010, 107, 7473–7478.

25. Kantarjian, H.M.; Thomas, X.G.; Dmoszynska, A.; Wierzbowska, A.; Mazur, G.; Mayer, J.; Gau, J.P.; Chou, W.C.; Buckstein, R.; Cermak, J.; et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. *J. Clin. Oncol.* 2012, 30, 2670–2677.

26. Quintas-Cardama, A.; Santos, F.P.; Garcia-Manero, G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. *Leukemia* 2011, 25, 226–235.

27. Bose, P.; Grant, S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. *Leuk. Res.* 2014, 38, 862–865.
28. Prebet, T.; Sun, Z.; Figueroa, M.E.; Ketterling, R.; Melnick, A.; Greenberg, P.L.; Herman, J.; Juckett, M.; Smith, M.R.; Malick, L.; et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia Intergroup trial E1905. *J. Clin. Oncol.* 2014, 32, 1242–1248.

29. Quintas-Cardama, A.; Kantarjian, H.M.; Ravandi, F.; Foudray, C.; Pemmaraju, N.; Kadia, T.M.; Borthakur, G.; Daver, N.G.; Faderl, S.; Jabbour, E.; et al. Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. *ASH Annu. Meet. Abstr.* 2012, 120, 3821.

30. Blum, W.; Schwind, S.; Tarighat, S.S.; Geyer, S.; Eisfeld, A.K.; Whitman, S.; Walker, A.; Klisovic, R.; Byrd, J.C.; Santhanam, R.; et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. *Blood* 2012, 119, 6025–6031.

31. Ravandi, F.; Alattar, M.L.; Gruenwald, M.R.; Rudek, M.A.; Rajkhowa, T.; Richie, M.A.; Pierce, S.; Daver, N.; Garcia-Manero, G.; Faderl, S.; et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood* 2013, 121, 4655–4662.

32. Levis, M. FLT3/ITD AML and the law of unintended consequences. *Blood* 2011, 117, 6987–6990.

33. Williams, C.B.; Kambhampati, S.; Fiskus, W.; Wick, J.; Dutreix, C.; Ganguly, S.; Aljitawi, O.; Reyes, R.; Fleming, A.; Abhyankar, S.; et al. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. *Pharmacotherapy* 2013, 33, 1341–1352.

34. Liesveld, J.L.; O’Dwyer, K.; Walker, A.; Becker, M.W.; Ifthikharuddin, J.J.; Mulford, D.; Chen, R.; Bechelli, J.; Rosell, K.; Minhajuddin, M.; et al. A phase I study of decitabine and rapamycin in relapsed/refractory AML. *Leuk. Res.* 2013, 37, 1622–1627.

35. Welch, J.S.; Niu, H.; Uy, G.L.; Westervelt, P.; Abboud, C.N.; Vij, R.; Stockler-Goldstein, K.E.; Jacoby, M.; Pusic, I.; Schroeder, M.A.; et al. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. *Am. J. Hematol.* 2014, 89, E103–E108.

36. Pollyea, D.A.; Kohrt, H.E.; Gallegos, L.; Figueroa, M.E.; Abdel-Wahab, O.; Zhang, B.; Bhattacharya, S.; Zehnder, J.; Liedtke, M.; Gotlib, J.R.; et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. *Leukemia* 2012, 26, 893–901.

37. Ramsingh, G.; Westervelt, P.; Cashen, A.F.; Uy, G.L.; Stockler-Goldstein, K.; Abboud, C.N.; Bernabe, N.; Monahan, R.; DiPersio, J.F.; Vij, R. A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. *Leukemia* 2013, 27, 725–728.

38. Bogenberger, J.M.; Kornblau, S.M.; Pierceall, W.E.; Lena, R.; Chow, D.; Shi, C.X.; Mantei, J.; Ahmann, G.; Gonzales, I.M.; Choudhary, A.; et al. BCL-2 family proteins as 5-Azacitidine-sensitizing targets and determinants of response in myeloid malignancies. *Leukemia* 2014, 28, 1657–1665.

39. Dawson, M.A.; Kouzarides, T.; Huntly, B.J. Targeting epigenetic readers in cancer. *N. Engl. J. Med.* 2012, 367, 647–657.

40. Belkina, A.C.; Denis, G.V. BET domain co-regulators in obesity, inflammation and cancer. *Nat. Rev. Cancer* 2012, 12, 465–477.
41. Filippakopoulos, P.; Knapp, S. Targeting bromodomains: Epigenetic readers of lysine acetylation. *Nat. Rev. Drug Discov.* 2014, 13, 337–356.

42. Fiskus, W.; Sharma, S.; Qi, J.; Valenta, J.A.; Schaub, L.J.; Shah, B.; Peth, K.; Portier, B.P.; Rodriguez, M.; Devaraj, S.G.; *et al.* Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. *Mol. Cancer Ther.* 2014, 13, 1142–1154.

43. Fiskus, W.; Sharma, S.; Qi, J.; Shah, B.; Devaraj, S.G.; Leveque, C.; Portier, B.P.; Iyer, S.P.; Bradner, J.E.; Bhalla, K.N. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. *Mol. Cancer Ther.* 2014, 13, 2315–2327.

44. Grant, S.; Dai, Y. Histone deacetylase inhibitors and rational combination therapies. *Adv. Cancer Res.* 2012, 116, 199–237.

45. Bose, P.; Dai, Y.; Grant, S. Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights. *Pharmacol. Ther.* 2014, 143, 323–336.

46. Bots, M.; Johnstone, R.W. Rational combinations using HDAC inhibitors. *Clin. Cancer Res.* 2009, 15, 3970–3977.

47. San-Miguel, J.F.; Hungria, V.T.; Yoon, S.S.; Bekscal, M.; Dimopoulos, M.A.; Elghandour, A.; Jedrzejczak, W.W.; Gunther, A.; Nakorn, T.N.; Siritanaratkul, N.; *et al.* Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. *Lancet Oncol.* 2014, 15, 1195–1206.

48. Dai, Y.; Chen, S.; Wang, L.; Pei, X.Y.; Kramer, L.B.; Dent, P.; Grant, S. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-kappaB and Bim. *Br. J. Haematol.* 2011, 153, 222–235.

49. Holkova, B.; Bose, P.; Tombes, M.B.; Shrader, E.; Wan, W.; Weir-Wiggins, C.; Stoddert, E.; Sankala, H.; Kmiecik, M.; Roberts, J.D.; *et al.* Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis—One Year Update. *ASH Annu. Meet. Abstr.* 2012, 120, 3588.

50. Batalo, M.S.; Bose, P.; Holkova, B.; Grant, S. Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition. In *Resistance to Proteasome Inhibitors in Cancer*; Ping Dou, Q., Ed.; Springer-Verlag: New York, NY, USA, 2014; pp. 149–179.

51. Karin, M. Nuclear factor-kappaB in cancer development and progression. *Nature* 2006, 441, 431–436.

52. Dai, Y.; Rahmani, M.; Dent, P.; Grant, S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. *Mol. Cell. Biol.* 2005, 25, 5429–5444.
53. Dai, Y.; Guzman, M.L.; Chen, S.; Wang, L.; Yeung, X.K.; Pei, X.Y.; Dent, P.; Jordan, C.T.; Grant, S. The NF (Nuclear factor)-kappaB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. *Br. J. Haematol.* 2010, 151, 70–83.

54. Hideshima, T.; Bradner, J.E.; Wong, J.; Chauhan, D.; Richardson, P.; Schreiber, S.L.; Anderson, K.C. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. *Proc. Natl. Acad. Sci. USA* 2005, 102, 8567–8572.

55. Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumarsawamy, S.; Boyapalle, S.; Atadja, P.; et al. Inhibition of histone deacetylase 6 acetylases and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. *J. Biol. Chem.* 2005, 280, 26729–26734.

56. Adams, J. The development of proteasome inhibitors as anticancer drugs. *Cancer Cell* 2004, 5, 417–421.

57. Adams, J. The proteasome: A suitable antineoplastic target. *Nat. Rev. Cancer* 2004, 4, 349–360.

58. Fotheringham, S.; Epping, M.T.; Stimson, L.; Khan, O.; Wood, V.; Pezzella, F.; Bernards, R.; la Thangue, N.B. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. *Cancer Cell* 2009, 15, 57–66.

59. Kikuchi, J.; Wada, T.; Shimizu, R.; Izumi, T.; Akutsu, M.; Mitsunaga, K.; Noborio-Hatano, K.; Nobuyoshi, M.; Ozawa, K.; Kano, Y.; et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. *Blood* 2010, 116, 406–417.

60. Bose, P.; Simmons, G.L.; Grant, S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. *Expert Opin. Investig. Drugs* 2013, 22, 723–738.

61. Chao, S.H.; Price, D.H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription *in vivo*. *J. Biol. Chem.* 2001, 276, 31793–31799.

62. Almenara, J.; Rosato, R.; Grant, S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). *Leukemia* 2002, 16, 1331–1343.

63. Rosato, R.R.; Almenara, J.A.; Cartee, L.; Betts, V.; Chellappan, S.P.; Grant, S. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. *Mol. Cancer Ther.* 2002, 1, 253–266.

64. Rosato, R.R.; Almenara, J.A.; Yu, C.; Grant, S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. *Mol. Pharmacol.* 2004, 65, 571–581.

65. Rosato, R.R.; Almenara, J.A.; Maggio, S.C.; Atadja, P.; Craig, R.; Vrana, J.; Dent, P.; Grant, S. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells. *Mol. Cancer Ther.* 2005, 4, 1772–1785.

66. Rosato, R.R.; Almenara, J.A.; Kolla, S.S.; Maggio, S.C.; Coe, S.; Gimenez, M.S.; Dent, P.; Grant, S. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions. *Mol. Cancer Ther.* 2007, 6, 692–702.
67. Holkova, B.; Supko, J.G.; Ames, M.M.; Reid, J.M.; Shapiro, G.I.; Perkins, E.B.; Ramakrishnan, V.; Tombes, M.B.; Honeycutt, C.; McGovern, R.M.; et al. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. *Clin. Cancer Res.* **2013**, *19*, 1873–1883.

68. Byrd, J.C.; Lin, T.S.; Dalton, J.T.; Wu, D.; Phelp, M.A.; Fischer, B.; Moran, M.; Blum, K.A.; Rovin, B.; Brooker-McEldowney, M.; et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. *Blood* **2007**, *109*, 399–404.

69. Nishioka, C.; Ikezoe, T.; Yang, J.; Takeuchi, S.; Koeffler, H.P.; Yokoyama, A. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. *Leuk. Res.* **2008**, *32*, 1382–1392.

70. Qiu, L.; Burgess, A.; Fairlie, D.P.; Leonard, H.; Parsons, P.G.; Gabrielli, B.G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. *Mol. Biol. Cell* **2000**, *11*, 2069–2083.

71. Stevens, F.E.; Beamish, H.; Warrener, R.; Gabrielli, B. Histone deacetylase inhibitors induce mitotic slippage. *Oncogene* **2008**, *27*, 1345–1354.

72. Yu, C.; Rahmani, M.; Almenara, J.; Subler, M.; Krystal, G.; Conrad, D.; Varticovski, L.; Dent, P.; Grant, S. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. *Cancer Res.* **2003**, *63*, 2118–2126.

73. Nimmanapalli, R.; Fuino, L.; Bali, P.; Gasparetto, M.; Glozak, M.; Tao, J.; Moscinski, L.; Smith, C.; Wu, J.; Jove, R.; et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. *Cancer Res.* **2003**, *63*, 5126–5135.

74. Nimmanapalli, R.; Fuino, L.; Stobaugh, C.; Richon, V.; Bhalla, K. Cytoreductive therapy with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr/Abl-positive human acute leukemia cells. *Blood* **2003**, *101*, 3236–3239.

75. Fiskus, W.; Pranpat, M.; Balasis, M.; Bali, P.; Estrella, V.; Kumaraswamy, S.; Rao, R.; Rocha, K.; Herger, B.; Lee, F.; et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. *Clin. Cancer Res.* **2006**, *12*, 5869–5878.

76. Fiskus, W.; Pranpat, M.; Bali, P.; Balasis, M.; Kumaraswamy, S.; Boyapalle, S.; Rocha, K.; Wu, J.; Giles, F.; Manley, P.W.; et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. *Blood* **2006**, *108*, 645–652.

77. Bali, P.; George, P.; Cohen, P.; Tao, J.; Guo, F.; Sigua, C.; Vishvanath, A.; Scuto, A.; Annavarapu, S.; Fiskus, W.; et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. *Clin. Cancer Res.* **2004**, *10*, 4991–4997.
78. Wang, Y.; Fiskus, W.; Chong, D.G.; Buckley, K.M.; Natarajan, K.; Rao, R.; Joshi, A.; Balusu, R.; Koul, S.; Chen, J.; et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009, 114, 5024–5033.

79. Novotny-Diermayr, V.; Hart, S.; Goh, K.C.; Cheong, A.; Ong, L.C.; Hentze, H.; Pasha, M.K.; Jayaraman, R.; Ethirajulu, K.; Wood, J.M. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2012, 2, e69.

80. Dai, Y.; Chen, S.; Venditti, C.A.; Pei, X.Y.; Nguyen, T.K.; Dent, P.; Grant, S. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood 2008, 112, 793–804.

81. Fiskus, W.; Wang, Y.; Joshi, R.; Rao, R.; Yang, Y.; Chen, J.; Kolhe, R.; Balusu, R.; Eaton, K.; Lee, P.; et al. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin. Cancer Res. 2008, 14, 6106–6115.

82. Nguyen, T.; Dai, Y.; Attkisson, E.; Kramer, L.; Jordan, N.; Nguyen, N.; Kolluri, N.; Muschen, M.; Grant, S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin. Cancer Res. 2011, 17, 3219–3232.

83. Lok, W.; Klein, R.Q.; Saif, M.W. Aurora kinase inhibitors as anti-cancer therapy. Anticancer Drugs 2010, 21, 339–350.

84. Kelly, K.R.; Ecsedy, J.; Mahalingam, D.; Nawrocki, S.T.; Padmanabhan, S.; Giles, F.J.; Carew, J.S. Targeting aurora kinases in cancer treatment. Curr. Drug Targets 2011, 12, 2067–2078.

85. Zhang, B.; Strauss, A.C.; Chu, S.; Li, M.; Ho, Y.; Shiang, K.D.; Snyder, D.S.; Huettner, C.S.; Shultz, L.; Holyoake, T.; et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010, 17, 427–442.

86. Dawson, M.A.; Curry, J.E.; Barber, K.; Beer, P.A.; Graham, B.; Lyons, J.F.; Richardson, C.J.; Scott, M.A.; Smyth, T.; Squires, M.S.; et al. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br. J. Haematol. 2010, 150, 46–57.

87. Tanaka, R.; Squires, M.S.; Kimura, S.; Yokota, A.; Nagao, R.; Yamauchi, T.; Takeuchi, M.; Yao, H.; Reule, M.; Smyth, T.; et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL+ leukemia cells. Blood 2010, 116, 2089–2095.

88. Podesta, J.E.; Sugar, R.; Squires, M.; Linardopoulos, S.; Pearson, A.D.; Moore, A.S. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leuk. Res. 2011, 35, 1273–1275.

89. Tse, A.N.; Carvajal, R.; Schwartz, G.K. Targeting checkpoint kinase 1 in cancer therapeutics. Clin. Cancer Res. 2007, 13, 1955–1960.

90. Dai, Y.; Grant, S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 2010, 16, 376–383.

91. Kastan, M.B.; Bartek, J. Cell-cycle checkpoints and cancer. Nature 2004, 432, 316–323.
92. Bucher, N.; Britten, C.D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. *Br. J. Cancer* **2008**, *98*, 523–528.

93. Stirewalt, D.L.; Kopecky, K.J.; Meshinchi, S.; Appelbaum, F.R.; Slovak, M.L.; Willman, C.L.; Radich, J.P. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. *Blood* **2001**, *97*, 3589–3595.

94. Seliger, B.; Papadileris, S.; Vogel, D.; Hess, G.; Brendel, C.; Storkel, S.; Ortel, J.; Kolbe, K.; Huber, C.; Huhn, D.; *et al.* Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. *Eur. J. Haematol.* **1996**, *57*, 230–240.

95. Faderl, S.; Kantarjian, H.M.; Estey, E.; Manshouri, T.; Chan, C.Y.; Rahman Elsaied, A.; Kornblau, S.M.; Cortes, J.; Thomas, D.A.; Pierce, S.; *et al.* The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. *Cancer* **2000**, *89*, 1976–1982.

96. Christiansen, D.H.; Andersen, M.K.; Pedersen-Bjergaard, J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. *J. Clin. Oncol.* **2001**, *19*, 1405–1413.

97. Rucker, F.G.; Schlenk, R.F.; Bullinger, L.; Kayser, S.; Teleanu, V.; Kett, H.; Habdank, M.; Kugler, C.M.; Holzmann, K.; Gaidzik, V.I.; *et al.* TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. *Blood* **2012**, *119*, 2114–2121.
105. Middeke, J.M.; Fang, M.; Cornelissen, J.J.; Mohr, B.; Appelbaum, F.R.; Stadler, M.; Sanz, J.; Baurmann, H.; Bug, G.; Schafer-Eckart, K.; et al. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood 2014, 123, 2960–2967.

106. Fan, J.; Li, L.; Small, D.; Rasool, F. Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: Implications for genomic instability and therapy. Blood 2010, 116, 5298–5305.

107. Sallmyr, A.; Fan, J.; Datta, K.; Kim, K.T.; Grosu, D.; Shapiro, P.; Small, D.; Rasool, F. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: Implications for poor prognosis in AML. Blood 2008, 111, 3173–3182.

108. Petruccelli, L.A.; Dupere-Richer, D.; Pettersson, F.; Retrouvey, H.; Skoulikas, S.; Miller, W.H., Jr. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells. PLoS ONE 2011, 6, e20987.

109. Kachhap, S.K.; Rosmus, N.; Collis, S.J.; Kortenhorst, M.S.; Wissing, M.D.; Hedayati, M.; Shabbeer, S.; Mendonca, J.; Deangeli, J.; Marchionni, L.; et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE 2010, 5, e11208.

110. Miller, K.M.; Tjeertes, J.V.; Coates, J.; Legube, G.; Polo, S.E.; Britton, S.; Jackson, S.P. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat. Struct. Mol. Biol. 2010, 17, 1144–1151.

111. Brazelle, W.; Kreahling, J.M.; Gemmer, J.; Ma, Y.; Cress, W.D.; Haura, E.; Altik, S. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS ONE 2010, 5, e14335.

112. Ha, K.; Fiskus, W.; Rao, R.; Balusu, R.; Venkannagari, S.; Nalabothula, N.R.; Bhalla, K.N. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage. Mol. Cancer Ther. 2011, 10, 1194–1206.

113. Sugimoto, K.; Sasaki, M.; Isobe, Y.; Tsutsui, M.; Suto, H.; Ando, J.; Tamayose, K.; Ando, M.; Oshimi, K. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene 2008, 27, 3091–3101.

114. Tse, A.N.; Sheikh, T.N.; Alan, H.; Chou, T.C.; Schwartz, G.K. 90-kDa heat shock protein inhibitor abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. Mol. Pharmacol. 2009, 75, 124–133.

115. Dai, Y.; Chen, S.; Kmieciak, M.; Zhou, L.; Lin, H.; Pei, X.Y.; Grant, S. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol. Cancer Ther. 2013, 12, 878–889.

116. Caldwell, J.T.; Edwards, H.; Buck, S.A.; Ge, Y.; Taub, J.W. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr. Blood Cancer 2014, 61, 1767–1773.

117. Porter, C.C.; Kim, J.; Fosmire, S.; Gearheart, C.M.; van Linden, A.; Baturin, D.; Zaberezhnyy, V.; Patel, P.R.; Gao, D.; Tan, A.C.; et al. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 2012, 26, 1266–1276.
Weisberg, E.; Nonami, A.; Chen, Z.; Liu, F.; Zhang, J.; Sattler, M.; Nelson, E.; Cowens, K.; Christie, A.L.; Mitsiades, C.; et al. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. *Leukemia* 2015, 29, 27–37.

Guertin, A.D.; Li, J.; Liu, Y.; Hurd, M.S.; Schuller, A.G.; Long, B.; Hirsch, H.A.; Feldman, I.; Benita, Y.; Toniatti, C.; et al. Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single Agent Anticancer Therapy. *Mol. Cancer Ther.* 2013, 12, 1442–1452.

Kreahling, J.M.; Gemmer, J.Y.; Reed, D.; Letson, D.; Bui, M.; Altioi, S. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. *Mol. Cancer Ther.* 2012, 11, 174–182.

Tibes, R.; Bogenberger, J.M.; Chaudhuri, L.; Hagelstrom, R.T.; Chow, D.; Buechel, M.E.; Gonzales, I.M.; Demuth, T.; Slack, J.; Mesa, R.A.; et al. RNAi screening of the kinome with cytarabine in leukemias. *Blood* 2012, 119, 2863–2872.

Van Linden, A.A.; Baturin, D.; Ford, J.B.; Fosmire, S.P.; Gardner, L.; Korch, C.; Reigan, P.; Porter, C.C. Inhibition of Wee1 sensitizes cancer cells to antimitabolite chemotherapeutics *in vitro* and *in vivo*, independent of p53 functionality. *Mol. Cancer Ther.* 2013, 12, 2675–2684.

Krajewska, M.; Heijink, A.M.; Bisselink, Y.J.; Seinstra, R.I.; Sillje, H.H.; de Vries, E.G.; van Vugt, M.A. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. *Oncogene* 2013, 32, 3001–3008.

Qi, W.; Xie, C.; Li, C.; Caldwell, J.; Edwards, H.; Taub, J.W.; Wang, Y.; Lin, H.; Ge, Y. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. *J. Hematol. Oncol.* 2014, 7, 53.

Guertin, A.D.; Martin, M.M.; Roberts, B.; Hurd, M.; Qu, X.; Miselis, N.R.; Liu, Y.; Li, J.; Feldman, I.; Benita, Y.; et al. Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. *Cancer Cell Int.* 2012, 12, 45.

Russell, M.; Levin, K.; Rader, J.; Belcastro, L.; Li, Y.; Martinez, D.; Pawel, B.R.; Shumway, S.D.; Maris, J.M.; Cole, K.A. Combination Therapy Targeting the Chk1 and Wee1 Kinases Demonstrates Therapeutic Efficacy in Neuroblastoma. *Cancer Res.* 2013, 73, 776–784.

Carrassa, L.; Chila, R.; Lupi, M.; Ricci, F.; Celenza, C.; Mazzoletti, M.; Broggini, M.; Damia, G. Combined inhibition of Chk1 and Wee1: In *vitro* synergistic effect translates to tumor growth inhibition *in vivo*. *Cell Cycle* 2012, 11, 2507–2517.

Zhou, L.; Zhang, Y.; Chen, S.; Kmiecik, M.; Leng, Y.; Lin, H.; Rizzo, K.A.; Dumur, C.I.; Ferreira-Gonzalez, A.; Dai, Y.; et al. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. *Leukemia* 2014, doi:10.1038/leu.2014.296.

Three more drugs judged “breakthroughs”. *Cancer Discov.* 2013, 3, doi:10.1158/2159-8290.CD-NB2013-142.

Archambault, V.; Glover, D.M. Polo-like kinases: Conservation and divergence in their functions and regulation. *Nat. Rev. Mol. Cell Biol.* 2009, 10, 265–275.

Lapenna, S.; Giordano, A. Cell cycle kinases as therapeutic targets for cancer. *Nat. Rev. Drug Discov.* 2009, 8, 547–566.

Smits, V.A.; Klompmaker, R.; Arnaud, L.; Rijksen, G.; Nigg, E.A.; Medema, R.H. Polo-like kinase-1 is a target of the DNA damage checkpoint. *Nat. Cell Biol.* 2000, 2, 672–676.
133. Takaki, T.; Trenz, K.; Costanzo, V.; Petronczki, M. Polo-like kinase 1 reaches beyond mitosis—Cytokinesis, DNA damage response, and development. *Curr. Opin. Cell Biol.* 2008, 20, 650–660.

134. Liu, X.S.; Song, B.; Liu, X. The substrates of Plk1, beyond the functions in mitosis. *Protein Cell* 2010, 1, 999–1010.

135. Gleixner, K.V.; Ferenc, V.; Peter, B.; Gruze, A.; Meyer, R.A.; Hadzijusufovic, E.; Cerny-Reiterer, S.; Mayerhofer, M.; Pickl, W.F.; Sillaber, C.; et al. Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536. *Cancer Res.* 2010, 70, 1513–1523.

136. Dasmahapatra, G.; Patel, H.; Nguyen, T.; Attkisson, E.; Grant, S. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. *Clin. Cancer Res.* 2013, 19, 404–414.

137. Soucy, T.A.; Smith, P.G.; Milhollen, M.A.; Berger, A.J.; Gavin, J.M.; Adhikari, S.; Brownell, J.E.; Burke, K.E.; Cardin, D.P.; Critchley, S.; et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. *Nature* 2009, 458, 732–736.

138. Swords, R.T.; Kelly, K.R.; Smith, P.G.; Garnsey, J.J.; Mahalingam, D.; Medina, E.; Oberheu, K.; Padmanabhan, S.; O’Dwyer, M.; Nawrocki, S.T.; et al. Inhibition of NEDD8-activating enzyme: A novel approach for the treatment of acute myeloid leukemia. *Blood* 2010, 115, 3796–3800.

139. Swords, R.T.; Erba, H.P.; DeAngelo, D.J.; Smith, P.G.; Pickard, M.D.; Dezube, B.J.; Giles, F.J.; Medeiros, B.C. The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 in Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study. *ASH Annu. Meet. Abstr.* 2010, 116, 658.

140. Rabut, G.; Peter, M. Function and regulation of protein neddylation. “Protein modifications: Beyond the usual suspects” review series. *EMBO Rep.* 2008, 9, 969–976.

141. Nawrocki, S.T.; Griffin, P.; Kelly, K.R.; Carew, J.S. MLN4924: A novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. *Expert Opin. Investig. Drugs* 2012, 21, 1563–1573.

142. Wang, M.; Medeiros, B.C.; Erba, H.P.; DeAngelo, D.J.; Giles, F.J.; Swords, R.T. Targeting protein neddylation: A novel therapeutic strategy for the treatment of cancer. *Expert Opin. Ther. Targets* 2011, 15, 253–264.

143. Lin, J.J.; Milhollen, M.A.; Smith, P.G.; Narayanan, U.; Dutta, A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. *Cancer Res.* 2010, 70, 10310–10320.

144. Milhollen, M.A.; Narayanan, U.; Soucy, T.A.; Veiby, P.O.; Smith, P.G.; Amidon, B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. *Cancer Res.* 2011, 71, 3042–3051.

145. Luo, Z.; Pan, Y.; Jeong, L.S.; Liu, J.; Jia, L. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells. *Autophagy* 2012, 8, 1677–1679.

146. Luo, Z.; Yu, G.; Lee, H.W.; Li, L.; Wang, L.; Yang, D.; Pan, Y.; Ding, C.; Qian, J.; Wu, L.; et al. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. *Cancer Res.* 2012, 72, 3360–3371.
147. Robert, T.; Vanoli, F.; Chiolo, I.; Shubassi, G.; Bernstein, K.A.; Rothstein, R.; Botrugno, O.A.; Parazzoli, D.; Oldani, A.; Minucci, S.; et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. *Nature* 2011, 471, 74–79.

148. Shubassi, G.; Robert, T.; Vanoli, F.; Minucci, S.; Foiani, M. Acetylation: A novel link between double-strand break repair and autophagy. *Cancer Res.* 2012, 72, 1332–1335.

149. Cantley, L.C. The phosphoinositide 3-kinase pathway. *Science* 2002, 296, 1655–1657.

150. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. *J. Clin. Oncol.* 2010, 28, 1075–1083.

151. Martelli, A.M.; Nyakern, M.; Tabellini, G.; Bortul, R.; Tazzari, P.L.; Evangelisti, C.; Cocco, L. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. *Leukemia* 2006, 20, 911–928.

152. Martelli, A.M.; Evangelisti, C.; Chiarini, F.; Grimaldi, C.; Manzoli, L.; McCubrey, J.A. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. *Expert Opin. Investig. Drugs* 2009, 18, 1333–1349.

153. Xu, Q.; Simpson, S.E.; Scialla, T.J.; Bagg, A.; Carroll, M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. *Blood* 2003, 102, 972–980.

154. Xu, Q.; Thompson, J.E.; Carroll, M. mTOR regulates cell survival after etoposide treatment in primary AML cells. *Blood* 2005, 106, 4261–4268.

155. Min, Y.H.; Eom, J.I.; Cheong, J.W.; Maeng, H.O.; Kim, J.Y.; Jeung, H.K.; Lee, S.T.; Lee, M.H.; Hahn, J.S.; Ko, Y.W. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable. *Leukemia* 2003, 17, 995–997.

156. Steelman, L.S.; Abrams, S.L.; Whelan, J.; Bertrand, F.E.; Ludwig, D.E.; Basecke, J.; Libra, M.; Stivala, F.; Milella, M.; Tafuri, A.; et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. *Leukemia* 2008, 22, 686–707.

157. Martelli, A.M.; Evangelisti, C.; Chiarini, F.; McCubrey, J.A. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. *Oncotarget* 2010, 1, 89–103.

158. Furman, R.R.; Sharman, J.P.; Coutre, S.E.; Cheon, B.D.; Pagel, J.M.; Hillmen, P.; Barrientos, J.C.; Zelenetz, A.D.; Kipps, T.J.; Flinn, I.; et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N. Engl. J. Med.* 2014, 370, 997–1007.

159. Gopal, A.K.; Kahl, B.S.; de Vos, S.; Wagner-Johnston, N.D.; Schuster, S.J.; Jurczak, W.J.; Flinn, I.W.; Flowers, C.R.; Martin, P.; Viardot, A.; et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. *N. Engl. J. Med.* 2014, 370, 1008–1018.

160. Rahmani, M.; Yu, C.; Reese, E.; Ahmed, W.; Hirsch, K.; Dent, P.; Grant, S. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. *Oncogene* 2003, 22, 6231–6242.

161. Rahmani, M.; Reese, E.; Dai, Y.; Bauer, C.; Payne, S.G.; Dent, P.; Spiegel, S.; Grant, S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. *Cancer Res.* 2005, 65, 2422–2432.
162. Reed, J.C. Bcl-2-family proteins and hematologic malignancies: History and future prospects. *Blood* 2008, 111, 3322–3330.

163. Davids, M.S.; Letai, A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. *J. Clin. Oncol.* 2012, 30, 3127–3135.

164. Willis, S.N.; Chen, L.; Dewson, G.; Wei, A.; Naik, E.; Fletcher, J.I.; Adams, J.M.; Huang, D.C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. *Genes Dev.* 2005, 19, 1294–1305.

165. Bose, P.; Grant, S. Bcl-2 family: Translational aspects. In *Targeted Therapy of Acute Myeloid Leukemia*; Andreeff, M., Ed.; Springer-Verlag: New York, NY, USA, 2015; pp. 67–94.

166. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; *et al.* An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 2005, 435, 677–681.

167. Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitter, M.J.; Nimmer, P.; *et al.* ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. *Cancer Res.* 2008, 68, 3421–3428.

168. Roberts, A.W.; Seymour, J.F.; Brown, J.R.; Wierda, W.G.; Kipps, T.J.; Khaw, S.L.; Carney, D.A.; He, S.Z.; Huang, D.C.; Xiong, H.; *et al.* Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. *J. Clin. Oncol.* 2012, 30, 488–496.

169. Mason, K.D.; Carpinelli, M.R.; Fletcher, J.I.; Collinge, J.E.; Hilton, A.A.; Ellis, S.; Kelly, P.N.; Ekert, P.G.; Metcalf, D.; Roberts, A.W.; *et al.* Programmed anuclear cell death delimits platelet life span. *Cell* 2007, 128, 1173–1186.

170. Wilson, W.H.; O’Connor, O.A.; Czuczman, M.S.; LaCasce, A.S.; Gerecitano, J.F.; Leonard, J.P.; Tulpule, A.; Dunleavy, K.; Xiong, H.; Chiu, Y.L.; *et al.* Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. *Lancet Oncol.* 2010, 11, 1149–1159.

171. Gandhi, L.; Camidge, D.R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Khaira, D.; Hann, C.L.; McKeegan, E.M.; Litvinovich, E.; Hemken, P.M.; *et al.* Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. *J. Clin. Oncol.* 2011, 29, 909–916.

172. Rudin, C.M.; Hann, C.L.; Garon, E.B.; Ribeiro de Oliveira, M.; Bonomi, P.D.; Camidge, D.R.; Chu, Q.; Giaccone, G.; Khaira, D.; Ramalingam, S.S.; *et al.* Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. *Clin. Cancer Res.* 2012, 18, 3163–3169.

173. Schoenwaelder, S.M.; Jarman, K.E.; Gardiner, E.E.; Hua, M.; Qiao, J.; White, M.J.; Josefsson, E.C.; Alwis, I.; Ono, A.; Willcox, A.; Andrews, R.K.; *et al.* Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopenia that undermines the hemostatic function of platelets. *Blood* 2011, 118, 1663–1674.

174. Souers, A.J.; Levenon, J.D.; Boghaert, E.R.; Ackler, S.L.; Catron, N.D.; Chen, J.; Dayton, B.D.; Ding, H.; Enschede, S.H.; Fairbrother, W.J.; *et al.* ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat. Med.* 2013, 19, 202–208.
175. BCL-2 Inhibitor Yields High Response in CLL and SLL. Cancer Discov. 2014, 4, doi:10.1158/2159-8290.CD-NB2013-178.

176. Pan, R.; Hogdal, L.J.; Benito, J.M.; Bucci, D.; Han, L.; Borthakur, G.; Cortes, J.; Deangelio, D.J.; Debose, L.; Mu, H.; et al. Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia. Cancer Discov. 2014, 4, 362–375.

177. Marcucci, G.; Moser, B.; Blum, W.; Stock, W.; Wetzler, M.; Kolitz, J.E.; Thakuri, M.; Carter, T.; Stuart, R.K.; Larson, R.A. A phase III randomized trial of intensive induction and consolidation chemotherapy {+/-} oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. ASCO Meet. Abstr. 2007, 25 (Suppl. 18), 7012.

178. O’Brien, S.; Moore, J.O.; Boyd, T.E.; Larratt, L.M.; Skotnicki, A.B.; Koziner, B.; Chanan-Khan, A.A.; Seymour, J.F.; Gribben, J.; Itri, L.M.; et al. 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J. Clin. Oncol. 2009, 27, 5208–5212.

179. Glaser, S.P.; Lee, E.F.; Trounson, E.; Bouillet, P.; Wei, A.; Fairlie, W.D.; Izon, D.J.; Zuber, J.; Rappaport, A.R.; Herold, M.J.; et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012, 26, 120–125.

180. Konopleva, M.; Contractor, R.; Tsao, T.; Samudio, I.; Ruvolo, P.P.; Kitada, S.; Deng, X.; Zhai, D.; Shi, Y.X.; Sneed, T.; et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10, 375–388.

181. Van Delft, M.F.; Wei, A.H.; Mason, K.D.; Vandenberg, C.J.; Chen, L.; Czabotar, P.E.; Willis, S.N.; Scott, C.L.; Day, C.L.; Cory, S.; et al. The BH3 mimic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10, 389–399.

182. Konopleva, M.; Watt, J.; Contractor, R.; Tsao, T.; Samudio, I.; Estrov, Z.; Bornmann, W.; Kantarjian, H.; Viallet, J.; Samudio, I.; et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimic GX15–070 (obatoclax). Cancer Res. 2008, 68, 3413–3420.

183. Dai, Y.; Grant, S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res. 2007, 67, 2908–2911.

184. Bose, P.; Grant, S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leuk. Res. Rep. 2013, 2, 12–14.

185. Rahmani, M.; Davis, E.M.; Bauer, C.; Dent, P.; Grant, S. Apoptosis induced by the kinase inhibitor BAY 43–9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 2005, 280, 35217–35227.

186. Chen, S.; Dai, Y.; Harada, H.; Dent, P.; Grant, S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007, 67, 782–791.

187. Zhang, W.; Konopleva, M.; Ruvolo, V.R.; McQueen, T.; Evans, R.L.; Bornmann, W.G.; McCubrey, J.; Cortes, J.; Andreeff, M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008, 22, 808–818.
188. Rahmani, M.; Aust, M.M.; Attkisson, E.; Williams, D.C., Jr.; Ferreira-Gonzalez, A.; Grant, S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. *Blood* 2012, 119, 6089–6098.

189. Chen, S.; Dai, Y.; Pei, X.Y.; Grant, S. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: Evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. *Mol. Cell. Biol.* 2009, 29, 6149–6169.

190. Wei, Y.; Kadia, T.; Tong, W.; Zhang, M.; Jia, Y.; Yang, H.; Hu, Y.; Tambaro, F.P.; Viallet, J.; O’Brien, S.; et al. The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15–070 has synergistic antileukemia activity by activating both apoptosis and autophagy. *Clin. Cancer Res.* 2010, 16, 3923–3932.

191. Konopleva, M.; Milella, M.; Ruvolo, P.; Watts, J.C.; Ricciardi, M.R.; Korchin, B.; McQueen, T.; Bornmann, W.; Tsao, T.; Bergamo, P.; et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. *Leukemia* 2012, 26, 778–787.

192. Vachhani, P.; Bose, P.; Rahmani, M.; Grant, S. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. *Physiol. Genomics* 2014, 46, 448–456.

193. Luo, J.; Manning, B.D.; Cantley, L.C. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. *Cancer Cell* 2003, 4, 257–262.

194. Manning, B.D.; Cantley, L.C. AKT/PKB signaling: Navigating downstream. *Cell* 2007, 129, 1261–1274.

195. Engelman, J.A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. *Nat. Rev. Cancer* 2009, 9, 550–562.

196. Tamburini, J.; Chapuis, N.; Bardet, V.; Park, S.; Sujobert, P.; Willems, L.; Ifrah, N.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeutic inhibition of both pathways. *Blood* 2008, 111, 379–382.

197. Park, S.; Chapuis, N.; Bardet, V.; Tamburini, J.; Gallay, N.; Willems, L.; Knight, Z.A.; Shokat, K.M.; Azar, N.; Viguie, F.; et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. *Leukemia* 2008, 22, 1698–1706.

198. Chapuis, N.; Tamburini, J.; Green, A.S.; Vignon, C.; Bardet, V.; Neyret, A.; Pannetier, M.; Willems, L.; Park, S.; Macone, A.; et al. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. *Clin. Cancer Res.* 2010, 16, 5424–5435.

199. Grant, S. Cotargeting survival signaling pathways in cancer. *J. Clin. Investig.* 2008, 118, 3003–3006.

200. Ricciardi, M.R.; McQueen, T.; Chism, D.; Milella, M.; Estey, E.; Kaldjian, E.; Sebolt-Leopold, J.; Konopleva, M.; Andreeff, M. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. *Leukemia* 2005, 19, 1543–1549.
201. Jin, L.; Tabe, Y.; Kojima, K.; Shikami, M.; Benito, J.; Ruvolo, V.; Wang, R.Y.; McQueen, T.; Ciurea, S.O.; Miida, T.; et al. PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment. *J. Mol. Med. (Berl.)* **2013**, *91*, 1383–1397.

202. Zhang, W.; Ruvolo, V.R.; Gao, C.; Zhou, L.; Bornmann, W.; Tsao, T.; Schober, W.D.; Smith, P.; Guichard, S.; Konopleva, M.; et al. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. *Mol. Cancer Ther.* **2014**, *13*, 1848–1859.

203. Rahmani, M.; Aust, M.M.; Attkisson, E.; Williams, D.C., Jr.; Ferreira-Gonzalez, A.; Grant, S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. *Cancer Res.* **2013**, *73*, 1340–1351.

204. Dai, Y.; Rahmani, M.; Grant, S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. *Oncogene* **2003**, *22*, 7108–7122.

205. Dai, Y.; Rahmani, M.; Pei, X.; Dent, P.; Grant, S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. *Blood* **2004**, *104*, 509–518.

206. Holkova, B.; Perkins, E.B.; Ramakrishnan, V.; Tombs, M.B.; Shrader, E.; Talreja, N.; Wellons, M.D.; Hogan, K.T.; Roodman, G.D.; Coppola, D.; et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. *Clin. Cancer Res.* **2011**, *17*, 3388–3397.

207. Holkova, B.; Kmieciak, M.; Perkins, E.B.; Bose, P.; Baz, R.; Roodman, G.D.; Stuart, R.K.; Ramakrishnan, V.; Wan, W.; Peer, C.J.; et al. Phase I Trial of Bortezomib and “Non-Hybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms. *Clin. Cancer Res.* **2014**, *20*, 5652–5662.

208. Yu, C.; Rahmani, M.; Dai, Y.; Conrad, D.; Krystal, G.; Dent, P.; Grant, S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. *Cancer Res.* **2003**, *63*, 1822–1833.

209. Thomas, D.; Powell, J.A.; Vergez, F.; Segal, D.H.; Nguyen, N.Y.; Baker, A.; Teh, T.C.; Barry, E.F.; Sarry, J.E.; Lee, E.M.; et al. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. *Blood* **2013**, *122*, 738–748.

210. Dai, Y.; Yu, C.; Singh, V.; Tang, L.; Wang, Z.; McInistry, R.; Dent, P.; Grant, S. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. *Cancer Res.* **2001**, *61*, 5106–5115.

211. Dai, Y.; Khanna, P.; Chen, S.; Pei, X.Y.; Dent, P.; Grant, S. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. *Blood* **2007**, *109*, 4415–4423.
212. Dai, Y.; Rahmani, M.; Pei, X.Y.; Khanna, P.; Han, S.I.; Mitchell, C.; Dent, P.; Grant, S. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. *Blood* **2005**, *105*, 1706–1716.

213. Roberts, E.C.; Shapiro, P.S.; Nahreini, T.S.; Pages, G.; Pouyssegur, J.; Ahn, N.G. Distinct cell cycle timing requirements for extracellular signal-regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell mitosis. *Mol. Cell. Biol.* **2002**, *22*, 7226–7241.

214. Wu, D.; Chen, B.; Parihar, K.; He, L.; Fan, C.; Zhang, J.; Liu, L.; Gillis, A.; Bruce, A.; Kapoor, A.; Tang, D. ERK activity facilitates activation of the S-phase DNA damage checkpoint by modulating ATR function. *Oncogene* **2006**, *25*, 1153–1164.

215. Golding, S.E.; Rosenberg, E.; Neill, S.; Dent, P.; Povirk, L.F.; Valerie, K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. *Cancer Res.* **2007**, *67*, 1046–1053.

216. Jain, N.; Curran, E.; Iyengar, N.M.; Diaz-Florez, E.; Kunnavakkam, R.; Popplewell, L.; Kirschbaum, M.H.; Harrison, T.; Erba, H.P.; Green, M.; *et al*. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: A University of Chicago phase II consortium trial. *Clin. Cancer Res.* **2014**, *20*, 490–498.

217. Pei, X.Y.; Dai, Y.; Felthousen, J.; Chen, S.; Takabatake, Y.; Zhou, L.; Youssefian, L.E.; Sanderson, M.W.; Bodie, W.W.; Kramer, L.B.; *et al*. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. *PLoS ONE* **2014**, *9*, e89064.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).